Jazz Pharmaceuticals plc (JAZZ) Valuation

Valuation

Model-based estimates, not advice. The DCF is the discounted-cash-flow value per share; compare it with the price, not as a target.

DCF fair value

+84.2%

$398.90

vs $216.58 price

Levered DCF

$588.21

After debt service

Piotroski score

8 / 9

Strong

Altman Z-score

2.36

Grey zone

Rating

A-

Overall 4 / 5

Ratios by fiscal year

Margins and yields are shares of revenue, equity or price; multiples are ×.

Metric	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018
P/E	-29.11×	13.59×	18.78×	-44.5×	-23.12×	38.56×	16.19×	16.64×
P/B	2.4×	1.86×	2.08×	3.23×	1.92×	2.51×	2.72×	2.7×
P/S	2.43×	1.87×	2.03×	2.72×	2.46×	3.89×	3.92×	3.93×
EV / EBITDA	54.8×	7.47×	8.33×	10.14×	12.81×	9.95×	9.49×	9.35×
Gross margin	88.2%	89.0%	88.6%	85.2%	85.8%	93.7%	94.1%	93.6%
Operating margin	5.3%	17.6%	15.1%	-1.8%	5.5%	16.0%	24.6%	32.5%
Net margin	-8.3%	13.8%	10.8%	-6.1%	-10.6%	10.1%	24.2%	23.6%
Current ratio	1.86×	4.46×	2.24×	2.79×	3.23×	4.34×	4.47×	3.57×
Debt / equity	1.26×	1.51×	1.55×	1.88×	1.55×	0.61×	0.57×	0.58×
Interest coverage	1.15×	3.01×	2×	-0.23×	0.61×	3.79×	7.37×	7.83×
Dividend yield	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Payout ratio	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%

Key metrics by fiscal year

Metric	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018
Return on equity	-8.2%	13.7%	11.1%	-7.3%	-8.3%	6.5%	16.8%	16.2%
Return on invested capital	1.2%	6.5%	5.5%	-0.4%	1.5%	5.4%	10.2%	10.7%
Return on assets	-3.1%	4.7%	3.6%	-2.1%	-2.7%	3.7%	9.4%	8.6%
Free cash flow yield	11.1%	17.7%	13.7%	7.8%	9.6%	5.7%	7.0%	9.0%
Earnings yield	-3.4%	7.4%	5.3%	-2.2%	-4.3%	2.6%	6.2%	6.0%
Enterprise value	$14.4B	$11.4B	$12.1B	$14.9B	$13.2B	$10.4B	$9.6B	$8.7B
Net debt / EBITDA	15.34×	2.46×	2.96×	3.36×	5.41×	1.14×	1.12×	1.38×
Cash conversion cycle (days)	285	394	481	486	872	229	149	88